-
CUSTOMIZATION OF A LARGE LANGUAGE MODEL APPROACH TO CAPTURE PSA AND IMAGING DERIVED REAL-WORLD PROGRESSION EVENTS IN PROSTATE CANCER
Mar 18, 2026, 21:38 PM -
CRITICAL APPRAISAL OF PATIENT ENGAGEMENT FRAMEWORKS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) AND HEALTH TECHNOLOGY ASSESSMENT (HTA)
Mar 18, 2026, 21:38 PM -
PHYSICIAN-LED CHART ABSTRACTION (PLCA) IN ONCOLOGY: ADVANCING FDA FIT-FOR-USE REAL-WORLD DATA FOR HEOR DECISION-MAKING
Mar 18, 2026, 21:38 PM -
APPLICATION OF CAUSAL FOREST TO IDENTIFY IMPORTANT FEATURES TO EVALUATE HETEROGENEOUS TREATMENT EFFECTS OF DISEASE-MODIFYING THERAPIES IN MULTIPLE SCLEROSIS
Mar 18, 2026, 21:38 PM -
A METHOD FOR CALCULATING THE TOTAL QALY OUTPUT AND THE MEAN COST/QALY ATTRIBUTABLE TO THE HEALTH SECTOR; THE CASE OF THE UK
Mar 18, 2026, 21:38 PM -
AUTOMATED AMCP DOSSIER DEVELOPMENT USING A RETRIEVAL-AUGMENTED GENERATION (RAG)-BASED MULTI-AGENT APPROACH
Mar 18, 2026, 21:38 PM -
FINANCIAL HARDSHIP, MEDICATION MANAGEMENT BEHAVIORS, AND PERCEIVED QUALITY OF CARE AMONG MEDICARE BENEFICIARIES
Mar 18, 2026, 21:38 PM -
VARIATION IN CASGEVY AND LYFGENIA COVERAGE CRITERIA ACROSS STATE MEDICAID PLANS
Mar 18, 2026, 21:38 PM -
SOCIODEMOGRAPHIC AND CLINICAL FACTORS ASSOCIATED WITH TIME TO TREATMENT INITIATION AND CARE PATHWAYS IN NON-METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA: A REAL-WORLD EVIDENCE STUDY
Mar 18, 2026, 21:38 PM -
ANTI-OSTEOPOROSIS DRUGS PRESCRIPTIONS AMONG OSTEOPOROSIS PATIENTS WITH T2DM IN CHINA
Mar 18, 2026, 21:38 PM -
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF INDIVIDUALS INITIATING GLP-1 AGONISTS FOR OBESITY: A CLAIMS DATABASE ANALYSIS IN THE US
Mar 18, 2026, 21:38 PM -
IMPACT OF ETEPLIRSEN TREATMENT INITIATION DELAYS ON LOSS OF AMBULATION INCIDENCE AMONG AMBULATORY PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS AMONG PEOPLE WITH MODERATE-TO-SEVERE HEMOPHILIA A AND B IN CHINA: A RETROSPECTIVE DATABASE STUDY
Mar 18, 2026, 21:38 PM -
LEVERAGING HEALTH INSURANCE DATA FOR ACCELERATED AND TARGETED RECRUITMENT IN CLINICAL TRIALS IN GERMANY
Mar 18, 2026, 21:38 PM -
EARLY EXPERIENCE WITH THE EUROPEAN UNION JOINT CLINICAL ASSESSMENT (EUJCA): IMPLICATIONS FOR ONCOLOGY PRODUCTS
Mar 18, 2026, 21:38 PM -
REAL-WORLD OUTCOMES OF SECOND-LINE THERAPIES IN RELAPSED/REFRACTORY DLBCL PATIENTS IN GERMANY: IMPACT OF FRONT-LINE TREATMENT-FREE PERIOD (2020-2022)
Mar 18, 2026, 21:38 PM -
ECONOMIC IMPACT OF AN AI-ENABLED DIGITAL TWIN INTERVENTION IN TYPE 2 DIABETES
Mar 18, 2026, 21:38 PM -
AN INDIRECT TREATMENT COMPARISON (ITC) OF IFINATAMAB DERUXTECAN (I-DXD) VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY (RWPCT) IN PATIENTS PREVIOUSLY TREATED WITH AT LEAST 2 LINES OF THERAPY (LOTS) FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER...
Mar 18, 2026, 21:38 PM -
THE EXTENT OF TREATMENT RESPONSE AND PREFERENCE HETEROGENEITY IN MAJOR DEPRESSIVE DISORDER: IMPLICATIONS FOR POPULATION-LEVEL RESOURCE ALLOCATION
Mar 18, 2026, 21:38 PM -
AN AUTOMATED FEASIBILITY ASSESSMENT TOOL FOR INDIRECT TREATMENT COMPARISONS ACROSS MULTIPLE ANALYTICAL METHODS
Mar 18, 2026, 21:38 PM
